Will the FDA approve Any psychedelic substance for medical use this year?

- [2026-04-18] President Trump signed Executive Order 14401 "Accelerating Medical Treatments for Serious Mental Illness," directing FDA to prioritize review of psychedelic compounds and DEA to streamline rescheduling for approved drugs. Trump signed an executive order which he stated would "dramatically accelerate access to new medical research and treatments based on psychedelic drugs," directing FDA to prioritize review of psychedelic compounds. - [2026-04-24] FDA announced it is accelerating regulatory action and issued Commissioner's National Priority Vouchers (CNPVs) to three companies: Compass Pathways (psilocybin/COMP360 for treatment-resistant depression), Usona Institute (psilocybin for MDD), and Transcend Therapeutics (methylone/TSND-201 for PTSD). "On April 24, 2026, the U.S. Food and Drug Administration issued National Priority Vouchers to three companies developing psychedelic-based therapies: Compass Pathways for its synthetic psilocybin (COMP360) for treatment-resistant depression; the Usona Institute for psilocybin for major depressive disorder; and Transcend Therapeutics for methylone (TSND-201, an MDMA-like compound) for PTSD." No drug has yet been approved — vouchers only accelerate review timing. "Neither national priority voucher issuance nor Breakthrough Therapy designation constitutes an FDA determination of safety or effectiveness, and neither is a substitute for marketing approval." - [2026-08-05/08-09] Compass Pathways' rolling NDA submission for COMP360 (psilocybin, TRD) is underway, with final submission still targeted for Q4 2026 and commercial launch not expected until H1 2027, contingent on both FDA approval and DEA rescheduling. "Final New Drug Application (NDA) submission on track for Q4... Rolling submission and initial review are underway, with some modules of the NDA submitted and on track to complete all modules in Q4." Progressing toward potential commercial launch in first half 2027. - [2026-08-09/08-10] Resilient Pharmaceuticals (formerly Lykos/MAPS PBC) quietly resubmitted its MDMA-assisted therapy NDA for PTSD (brand name potentially "Rysanso") without conducting the new Phase 3 trial the FDA's 2024 Complete Response Letter had called for. "Resilient Pharmaceuticals... has resubmitted its new drug application (NDA) for MDMA-assisted therapy for PTSD to the U.S. Food and Drug Administration (FDA)... The resubmission follows the Complete Response Letter issued on August 9, 2024, which recommended additional research related to durability of response, safety characterization, and steps to minimize potential for bias." - [2026-08-12] Analysts note the FDA has not indicated whether the resubmitted MDMA package resolves the durability, safety, and bias concerns raised in the 2024 CRL, and the agency's Division of Psychiatry — described as insulated from political pressure — remains the ultimate decision-maker. "it is now up to the agency to appraise the reconstituted package and decide whether to approve the MDMA candidate... it is our understanding, however, that the Division of Psychiatry remains somewhat sheltered from those external forces, and is empowered as the ultimate decision-maker." - [2026-08-12] Industry trackers expect Compass Pathways and Usona to submit completed psilocybin NDAs later in 2026, and note it is "too close to call" which candidate (MDMA vs. psilocybin) might reach an approval decision first. Article notes expectation that Compass Pathways and Usona Institute would both aim to submit psilocybin NDAs later in 2026, with reviews potentially as brief as 1-2 months under vouchers. - [2026-07-13/07-14] FDA finalized its guidance "Psychedelic Drugs: Considerations for Clinical Investigations" and scheduled a Part 15 public hearing for September 14, 2026, on "potential future therapeutic use" of psychedelic drugs — explicitly framed as forward-looking, not an approval action. The hearing sought "feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings." - [2026-09-14] FDA held the scheduled public Part 15 hearing on psychedelic drugs at its White Oak campus, per the official FDA meeting notice; this was a comment-gathering event, not a decision point. - [2026-08-07] Independent regulatory trackers confirm that as of mid-2026 no psychedelic drug is FDA-approved for any psychiatric indication. "Psilocybin is not FDA-approved for any psychiatric indication as of July 2026. Compass Pathways is completing a rolling New Drug Application for COMP360 in treatment-resistant depression, targeting Q4 2026 for final submission, with commercial launch anticipated in the first half of 2027 subject to FDA approval and DEA rescheduling." - [2026-05-05] Former FDA Commissioner Marty Makary told NBC News the first psychedelic drug "might" be approved this year, reflecting optimistic administration messaging rather than a confirmed timeline. "Martin Makary told NBC News that the first psychedelic drug might be approved this year." - [2026-09-25] The FDA's own psychedelic drugs resource page (last updated 2026-07-13) lists only guidance documents, vouchers, the September hearing, and an FDA-VA data-sharing MOU — no approval or approval decision is listed. Source: FDA official page. NOT FOUND: No evidence of any Complete Response Letter, approval, or rejection decision issued on the Resilient MDMA resubmission or on any Compass/Usona/Transcend NDA as of September 25, 2026; no confirmed FDA decision date has been announced for any of these applications (Compass's own timeline points to a decision no earlier than late 2026/early 2027, with commercial launch expected H1 2027). BOTTOM LINE: As of September 25, 2026, no psychedelic substance has been approved by the FDA; the most advanced candidates (Resilient's MDMA/Rysanso resubmission, filed August 2026, and Compass Pathways' rolling COMP360 psilocybin NDA, final submission expected Q4 2026) are still under review, with Compass itself projecting a decision in "late 2026 or early 2027" and commercial launch only in H1 2027 — leaving a narrow but nonzero window for a Yes resolution before the Jan 1, 2027 deadline.

- [2024-08-09] The FDA issued a Complete Response Letter rejecting Lykos Therapeutics' (MAPS) MDMA-assisted therapy NDA for PTSD, after an advisory committee voted 9-2 that effectiveness was not established and 10-1 against benefit-risk, citing near-total functional unblinding in the phase 3 trials and trial-conduct concerns . This is the only classic psychedelic to have reached a formal FDA marketing decision, and the base-rate outcome was a rejection, not an approval. - [2026-08-10] The sponsor (renamed Resilient Pharmaceuticals) resubmitted the NDA in august 2026 — without a new efficacy trial , relying instead on VA follow-up data, a small Phase 1 cardiac-safety study, and a third-party audit rather than the additional Phase 3 trial the 2024 CRL demanded. Historical resubmission review clocks ("class 2," ~6 months) mean a decision plausibly lands around February 2027 -timeframe, i.e., after the market's Jan 1, 2027 deadline. - [2026-08-17] Independent tracking of every psychedelic program shows psilocybin (COMP360/Compass Pathways) is furthest along after positive Phase 3 trials, but the final NDA module [is] on track for Q4 2026, launch targeted H1 2027 pending approval and DEA rescheduling — implying no approval is realistically expected before Jan 1, 2027. - [2026-08-17] The same tracker states plainly that no classic psychedelic — psilocybin, MDMA, LSD, DMT, ibogaine — is FDA-approved for anything as of august 2026 , underscoring a 100% historical non-approval rate for classic (serotonergic/entactogenic) psychedelics to date. - [2026-07-13] FDA's own psychedelic-drugs resource page confirms the agency has only reached the stage of supporting the development of psychedelic drugs, including new treatments for serious mental health conditions , with guidance and hearings, not any completed approval action for a classic psychedelic. - [2026-04-18] President Trump signed an executive order to "dramatically accelerate access to new medical research and treatments based on psychedelic drugs" , directing FDA to prioritize review — a policy tailwind, but experts note this does not guarantee FDA product approval, as the design and conduct of psychedelic therapy clinical trials is inherently challenging . - [2026-04-24] Following the EO, FDA announced a series of regulatory actions to support the development of serotonin-2A agonists and related products , including issuing National Priority Vouchers, but these are process accelerators, not approvals. - [2026-05-05] Even FDA Commissioner Martin Makary's own framing was speculative: he told NBC News that the first psychedelic drug might be approved this year — an optimistic forecast from an interested official, not a confirmed timeline, and one only source has repeated. - [2026-09-14] FDA is still at the input-gathering stage on psychedelics broadly, holding a public "Part 15" hearing on the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings , with comments due October 5, 2026 — a step that typically precedes rulemaking/guidance, not an imminent approval. - [2026-08-18] Analysts explicitly caution that Breakthrough Therapy designation (held by MDMA since 2017, psilocybin since 2018/2019) is routinely misread as near-approval... MDMA-assisted therapy held breakthrough designation from august 2017 and was rejected in 2024 — a directly relevant precedent showing designations/vouchers do not reliably predict near-term approval. BOTTOM LINE: The historical base rate for classic psychedelic FDA approvals is 0-for-1 (MDMA rejected in 2024), and the two most advanced 2026 candidates (MDMA resubmission with a ~6-month review clock starting August 2026, and psilocybin's NDA not even fully filed until Q4 2026) both have expected decision/launch timelines that land at or after, not before, the January 1, 2027 deadline — making a Yes resolution on this outside-view basis unlikely, though not impossible given political pressure to accelerate review. NOT FOUND: No official FDA PDUFA date has been published for the Resilient/MDMA resubmission or for any Compass Pathways psilocybin NDA (filing not yet complete); no betting-market or prediction-market historical track record specific to psychedelic FDA approvals was found beyond the Kalshi market itself.

- [2026-08-12] Psychedelic Alpha's detailed reporting states Resilient's resubmission relies on a VA long-term follow-up study, a new 32-person Phase I cardiac-safety trial, and a third-party audit of the original Phase 3 data rather than a fresh Phase 3 trial, and notes that "Resilient is presumably hoping that it has addressed FDA's dealbreakers, and it is now up to the agency to appraise the reconstituted package." The same source notes a Memorandum of Understanding between FDA and VA "envisages data sharing between the two federal bodies," which could feed VA data into the review. https://psychedelicalpha.com/news/two-years-after-rejection-resilient-quietly-refiles-mdma-for-ptsd-application/ - [2026-08-12] The same reporting notes that "the appraisal of a resubmission is often quicker than that of a new submission" — a structural reason Resilient's MDMA package could reach a decision faster than a first-time NDA, potentially inside the 2026 window despite lacking a CNPV voucher. - [2026-04-24] Multiple primary/company sources confirm the core mechanism for a fast YES path: "a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA's rigorous safety and efficacy standards." https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx - [2026-08-05] Compass Pathways' own Q2 2026 earnings release confirms "Rolling NDA submission and initial review underway and final submission expected to be completed in Q4" — meaning under the voucher's 1-2 month post-filing review clock, a decision could plausibly land in November or December 2026, before the Jan 1, 2027 deadline, even though commercial launch is targeted for H1 2027 (launch depends on separate DEA rescheduling, not the FDA decision itself). https://www.sec.gov/Archives/edgar/data/0001816590/000181659026000059/q22026pressrelease.htm - [2026-09-17] At the Deutsche Bank 2026 Healthcare Summit, Compass management reiterated it is "in rolling review with the FDA" and that COMPASS said COMP360 "could become the first classic psychedelic medicine to reach the market, with a launch expected in the first half of 2027." Notably, management framed FDA approval as a distinct, earlier step preceding the DEA/state rescheduling sequence needed for actual launch — meaning the question's resolution trigger (FDA marketing approval) could occur well before the H1 2027 commercial-launch date. https://www.investing.com/news/transcripts/compass-pathways-at-deutsche-bank-summit-launch-nears-for-comp360-93CH-4906106 - [2026-09-17] Compass executives stated that post-approval DEA rescheduling "by statute" takes 90 days, but added that a prior executive order "could help shorten that period," reinforcing that the political/regulatory environment is actively being engineered to compress every step in the chain, not just the FDA review itself. - [2026-08-12] Psychedelic Alpha states plainly that among the leading candidates it is "perhaps too close to call... between Resilient and the psilocybin developers" for which one reaches an FDA decision first — indicating informed industry trackers see genuine, non-trivial odds of a decision (positive or negative) landing within the market's window, not a near-certain 2027+ delay. - [2026-08-07] A tracker frames the CNPV mechanism as the decisive variable: "A National Priority Voucher shortens the FDA's standard new drug review from roughly ten to twelve months down to approximately one to two months," which the same source calls "the single most consequential number in the policy picture" for how fast approval could arrive. - [2026-09-21] Psychedelic Alpha continues active weekly coverage of "Psychedelics Week in Washington D.C." and FDA framework developments as of Sept 18-21, 2026, indicating sustained, high-tempo regulatory and political engagement rather than a stalled process — consistent with an administration still pushing for a 2026 approval milestone. https://psychedelicalpha.com/news/field-notes-5-psychedelics-week-in-washington-d-c/ - [2026-09-25] A Robinhood/Kalshi-linked prediction market on this identical question was pricing a "Before 2027" YES outcome at roughly 24 cents as of the search snapshot, indicating that informed traders assign a real, non-negligible (roughly one-in-four) chance to a 2026 approval despite the tight timeline. https://robinhood.com/us/en/prediction-markets/technology/events/will-the-fda-approve-any-psychedelic-substance-for-medical-use-before-2027-jan-06-2026/ - [2026-05-13] Leadership turnover at FDA (Makary departed as Commissioner in May 2026, succeeded by Kyle Diamantas in an acting capacity) has not been shown to have slowed the psychedelic-acceleration push; the CNPV program, rolling reviews, and voucher structure were institutionalized under Executive Order and FDA policy rather than tied to one individual, supporting continuity of the accelerated pathway. https://en.wikipedia.org/wiki/Marty_Makary NOT FOUND: No confirmed PDUFA/target action date has been published by FDA for either the Resilient MDMA resubmission or any Compass/Usona NDA; no evidence Compass has yet completed its "final" NDA submission (still targeted Q4 2026) that would start the 1-2 month CNPV clock; no statement from FDA itself (as opposed to company/industry sources) committing to a decision before Jan 1, 2027. BOTTOM LINE: The clearest mechanical path to a YES is Compass Pathways' CNPV-accelerated psilocybin (COMP360) review — if the "final" NDA module is filed early in Q4 2026 as planned, the voucher's 1-2 month review clock could produce an FDA decision in November-December 2026, before the deadline, with Resilient's faster-moving MDMA resubmission representing a second, "too close to call" contender industry trackers view as live in the same window.

- **[2026-08-05]** Compass Pathways' own Q2 2026 filing states the company's rolling NDA submission and initial review is underway with final submission expected to be completed in Q4 , and separately that commercial launch is expected in first half of 2027 — i.e., the company itself does not expect the drug on the market until after the Jan 1, 2027 deadline, and an FDA approval decision would need to land well before that self-projected launch window, which the company has never moved earlier. - **[2026-09-17]** At the Deutsche Bank Healthcare Summit, Compass management said the drug still faces regulatory steps ahead before a planned 2027 launch, with a large opportunity that will depend on approval, DEA rescheduling, state action and payer adoption — a recent, direct company statement confirming the approval decision itself is not expected imminently. - **[2026-09-23]** At the TD Cowen Neuropsychiatry Summit, Compass disclosed that a FDA typically takes about 60 days to accept an NDA filing, and a 30-day to 60-day approval target discussed by the FDA division director was described as aspirational rather than a commitment , and separately flagged that regulatory timing remains uncertain because FDA review, DEA rescheduling and state-level actions may not move at the same pace — the sponsor itself is hedging against a fast approval, undercutting bullish "vouchers mean fast approval" narratives. - **[2026-08-17]** An independent tracker states plainly that Compass's final NDA submission targets Q4 2026, with a potential FDA decision by late 2026 or early 2027 — meaning even the most advanced psilocybin candidate has a decision window that straddles, and could easily fall after, the Jan 1, 2027 resolution deadline. - **[2026-08-21]** Psychedelic Alpha, the most specialized industry tracker, frames the MDMA resubmission's fate as still entirely undecided, noting it is now up to the agency to appraise the reconstituted package and decide whether to approve the MDMA candidate , while cautioning that the Division of Psychiatry remains somewhat sheltered from external political forces and is empowered as the ultimate decision-maker — directly rebutting assumptions that political pressure guarantees a fast "Yes." - **[2026-08-21]** The same source notes Resilient's package still lacks a new Phase 3 trial, so Resilient may be open to a bit of back-and-forth with the Division, if the latter is inclined to approve the package in some form , implying negotiation/iteration (e.g., a further information request) rather than a clean approval is plausible — any such back-and-forth would consume the review clock further. - **[2026-08-21]** No PDUFA date or Class 1/2 filing-acceptance determination for the Resilient resubmission has been publicly disclosed; standard FDA practice classifies most CRL resubmissions as Class 2 with a Class 2 resubmissions within 6 months of the receipt date review clock — an August 9, 2026 filing under a standard Class 2 timeline would put a decision around February 2027, after the deadline, unless FDA affirmatively expedites it (unconfirmed). - **[2026-09-02]** A government shutdown that could have halted new drug-application intake and slowed FDA operations right before the Jan 1, 2027 deadline was averted only when Congress moved early, passing a continuing resolution that President Trump signed into law on September 2, 2026, nearly a full month before the deadline , extending funding only through December 11, 2026 — a fresh funding cliff sits just three weeks before the market's Jan 1, 2027 close, and history shows real disruption risk: the FY2026 shutdown from Oct 1–Nov 12, 2025 caused FDA to stop accepting new drug submissions for review while the government is shut down, but continue to process existing drugs under review . A repeat lapse after Dec 11, even if it doesn't stop ongoing reviews, adds headline risk and potential slippage to any late-2026 decision timelines. - **[2026-08-24]** Even sympathetic psychedelic-industry press treats MDMA approval as conditional and unresolved, describing the process only as pending re-review: "If approved by the FDA upon re-review, the official name of Resilient's patented MDMA formula is likely to hit the market as 'Rysanso'" — framing that presumes approval is not yet decided, not imminent. - **[2024→2026 base rate]** The only classic psychedelic ever to reach a full FDA marketing decision (MDMA/Lykos, Aug 2024) was rejected outright, with the FDA specifically requiring a third Phase 3 trial: the FDA ultimately decided to follow its advisory panel's recommendations and reject Lykos Therapeutics's NDA for MDMA-assisted psychotherapy for PTSD in August 2024, requesting further data on effectiveness and safety, including requiring a third phase 3 trial . Resilient's 2026 resubmission explicitly proceeds without that trial, meaning the agency's stated 2024 bar has not technically been met on paper — a live rejection risk, not just a timing risk. - **[2026-09-14]** The FDA's Part 15 hearing, with public comments due October 5, 2026, is explicitly a policy-input step, not a review milestone for any pending NDA — the agency's most recent public psychedelics-focused action (per prior team research) remains forward-looking guidance/consultation rather than adjudication of a specific application, reinforcing that no formal decision clock has visibly started ticking toward a pre-Jan-1 outcome. BOTTOM LINE: Every publicly disclosed timeline from the two lead sponsors (Compass's Q4 2026 filing/H1 2027 launch; Resilient's un-dated, non-guaranteed Class 2-style resubmission review) points to a decision window that lands at or after the Jan 1, 2027 deadline, the sole historical precedent for a classic psychedelic (MDMA, 2024) ended in rejection rather than approval, and a fresh government-funding cliff on Dec 11, 2026 adds tail risk of disruption in the final weeks of the window — all favoring a NO resolution. NOT FOUND: No PDUFA goal date or Class 1/2 filing-acceptance letter for Resilient's MDMA resubmission; no confirmation that Compass, Usona, or Transcend have completed (vs. merely begun) their NDA filings as of Sept 25, 2026; no evidence FDA has issued any Complete Response Letter, approval, or interim decision on any 2026 psychedelic application.